Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans
Clinical Infectious Diseases·
- DOI
- 10.1093/cid/cis327
- PMID
- 22441650
- PMCID
- PMC3369564
- OpenAlex
- W2098337510
- Study type
- Journal article
- Publisher
- Oxford University Press (OUP)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The vaccine targets conserved internal antigens shared across all influenza A subtypes, suggesting potential for broad protection against multiple strains not covered by current seasonal vaccines.
Structured evidence summary
Research question
The study assessed whether a novel T-cell-based influenza vaccine (MVA-NP+M1) designed to boost cross-reactive immune responses to conserved internal influenza A antigens could provide protection against influenza challenge in humans.
Study design
A phase 2a randomized controlled vaccination and influenza challenge study was conducted. Volunteers received either a single dose of MVA-NP+M1 or no vaccination, followed by intranasal challenge with influenza A/Wisconsin/67/2005 in a quarantine setting.
Population and setting
Healthy adult volunteers without measurable pre-existing serum antibodies to the challenge influenza strain (A/Wisconsin/67/2005) were enrolled.
Main findings
Following vaccination, volunteers exhibited significantly increased T-cell responses to vaccine antigens. Laboratory-confirmed influenza developed in 2 of 11 vaccinees compared with 5 of 11 control subjects. Among those who developed influenza, vaccinees experienced significantly fewer days of virus shedding (mean 0.45 days versus 1.09 days in controls, P = .036), and symptoms were less pronounced.
Public-health relevance
The vaccine targets conserved internal antigens shared across all influenza A subtypes, suggesting potential for broad protection against multiple strains not covered by current seasonal vaccines.
Important limitations
The study comprised a small sample size (n=22 total) and used a single challenge strain in a controlled quarantine setting, which limits generalizability to natural infection in broader populations. This summary is limited to the supplied single-article abstract and metadata; original paper review is required for decision-grade interpretation.
GIDS interpretation
This preliminary evidence demonstrates proof-of-concept for T-cell-based influenza vaccine efficacy in a controlled human challenge model, providing context for vaccine platform discoverability. No direct connection to live surveillance signals is supported by the evidence presented.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.